13F reference period
Q2 2026
Security Snapshot
Nasus Pharma Ltd - Common Stock (NSRX) Institutional Ownership
CUSIP: M7071P109
13F Institutional Holders and Ownership History from Q3 2025 to Q2 2026
Institutions Reporting
10
Shares (Excl. Options)
2.15M
Full value: 2,150,411 · shares · 30 Jun 2026Price
$3.50
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- NSRX on NYSE
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 2,150,411
- Total 13F value
- $7,526,440
- Portfolio coverage rank
- 0%
- Share change
- -23,863
- Value change
- +$29,207
- Number of holders
- 10
- Shares outstanding
- 11,710,801
- SEC-reported price per share
- $3.63
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- NSRX - Nasus Pharma Ltd - Common Stock is tracked under CUSIP M7071P109.
- 10 institutions reported positions in Q2 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 9 to 10 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$4.83M
Full value: $4,826,539 · USD · 31 Mar 2026.$7.53M
Full value: $7,526,440 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 10 institutions filings for Q2 2026.
Security key
M7071P109
13F reference period
Q2 2026
13F holders
10
13D/G owners
6
CIK / CUSIP context first
Open Q2 2026 holders
NSRX full holder history
Nasus Pharma Ltd SEC filings
Nasus Pharma Ltd company facts
Nasus Pharma Ltd insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP M7071P109:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
6
Security
NSRX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Gilboa Udi | 21% | $14,354,898 | 1,901,311 | Udi Gilboa | 30 Sep 2025 | |||
| Megiddo Dalia | 21% | $14,260,991 | 1,888,873 | Dr. Dalia Megiddo | 30 Sep 2025 | |||
| Hershman Ronnie | 15% | $10,445,516 | 1,383,512 | Dr. Ronnie Hershman | 30 Sep 2025 | |||
| BALYASNY ASSET MANAGEMENT L.P. | 10% | 0% | $3,603,320 | -$3.08 | 1,169,909 | -0% | BALYASNY ASSET MANAGEMENT L.P. | 30 Jun 2026 |
| Funicular Funds, LP | 5.2% | $3,309,730 | 612,913 | Funicular Funds, LP | 31 Mar 2026 | |||
| Capital Point Ltd. | 6.4% | 575,129 | Capital Point Ltd. | 14 Aug 2025 |
As of 30 Jun 2026,
10
institutional investors reported holding
shares of
Nasus Pharma Ltd - Common Stock (NSRX).
This represents
18%
of the company’s total
outstanding shares.
2.15M
Full value: 2,150,411 · shares · 30 Jun 202611.71M
Full value: 11,710,801 · shares · Stored outstanding share count13F concentration
Top 13 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
18%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Balyasny Asset Management L.P. | 7.7% | 898,473 | 0% | 0.01% | $3,144,656 |
| Cable Car Capital, LP | 5.3% | 616,081 | +2.3% | 0.05% | $2,156,284 |
| Velan Capital Investment Management LP | 3.1% | 359,390 | 0% | 0.77% | $1,257,865 |
| Hudson Bay Capital Management LP | 1.2% | 134,771 | 0% | 0% | $471,699 |
| Bleichroeder LP | 0.77% | 89,848 | 0% | 0.06% | $314,468 |
| CITADEL ADVISORS LLC | 0.19% | 22,004 | 0% | $77,014 | |
| XTX Topco Ltd | 0.14% | 16,640 | 0% | $58,240 | |
| RENAISSANCE TECHNOLOGIES LLC | 0.1% | 12,200 | 0% | $42,700 | |
| MORGAN STANLEY | 0.01% | 1,000 | -50% | 0% | $3,500 |
| Caitong International Asset Management Co., Ltd | 0% | 4 | 0% | $14 | |
| UBS Group AG | 0% | 0 | -100% | $0 | |
| HRT FINANCIAL LP | 0% | 0 | -100% | $0 | |
| Empery Asset Management, LP | 0% | 0 | -100% | $0 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
4
Headline period
Q2 2026
Rows shown
1-4 of 4